Table 8.
Events leading to withdrawal during the overall study follow‐up (except cardiac death)
| Treatment group | |||
|---|---|---|---|
| Torasemide n = 180 | Furosemide n = 186 | P‐value | |
| Mortality, n (%) | 12 (7) | 8 (4) | 0.32 |
| Renal, n (%) | 8 (4) | 4 (2) | 0.22 |
| Other (trauma, gunshot wound, pyometra…), n (%) | 4 (2) | 4 (2) | 1.00 |
| Adverse events, n (%) | 23 (13) | 15 (8) | 0.14 |
| Cardiaca, n (%) | 3 (2) | 1 (1) | 0.36 |
| Renal, n (%) | 2 (1) | 0 (0) | 0.24 |
| Electrolytes disorders, n (%) | 3 (2) | 8 (4) | 0.14 |
| Others (e.g, Cushing syndrome, neurological disorders, hepatic diseases (neoplasia and hepatobiliary inflammatory disorders), pyometra, arthrosis), n (%) | 15 (8) | 6 (3) | 0.036 |
a
Adverse cardiac events correspond to a worsening of congestive heart failure class severe enough to lead to withdrawal from the study (i.e, 4 of the 35 dogs of Table 6).
P‐values that appear in bold are < 0.05.